Latest news with #B-BodyExpress™
Yahoo
13-05-2025
- Business
- Yahoo
Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors
MADISON, Wis., May 13, 2025--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra. About Invenra Inc. Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies to address unmet therapeutic needs. At the core of Invenra's innovation is the proprietary B-Body® platform, a highly developable bispecific antibody scaffold engineered for superior yield, purity, stability, and compatibility with standard manufacturing processes. This platform enables the rapid generation of bispecific and multispecific antibodies with excellent biophysical properties, facilitating their progression from discovery through clinical development. To further accelerate antibody development, Invenra offers the B-Body Express™ Antibody Expression service, providing partners with swift access to high-quality bispecific antibodies derived from their own sequences. This service delivers fully QC-analyzed antibodies within weeks, supporting expedited preclinical research timelines. Invenra collaborates with pharmaceutical and biotechnology companies worldwide, contributing its expertise in antibody discovery and development. The company's participation in industry events, such as PEGS Boston, underscores its commitment to advancing bispecific antibody technologies and fostering partnerships that translate innovative science into transformative therapies. View source version on Contacts Bryan Glaser, Vice President of Business Developmentbglaser@ 608-441-8319https:// Sign in to access your portfolio
Business Wire
22-04-2025
- Business
- Business Wire
Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express ™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology. B-Body Express ™ allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express ™ service to include standardized 2x1 and 2x2 B-Body® formats in the near future. B-Body Express ™ - Validation Scale Service Features: Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales. Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation. Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility. Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon. Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms. "Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "Our B-Body Express ™ service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability." The B-Body® platform is engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieve yields of 6–11 g/L, >95% purity after a single purification step, and exhibit excellent stability and viscosity profiles —ideal for subcutaneous administration and standard manufacturing workflows. Starting from validated partner sequences, B-Body Express ™ manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development. About Invenra Inc. Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the new B-Body Express ™ service, to accelerate the journey of novel medicines to patients.
Yahoo
22-04-2025
- Business
- Yahoo
Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
MADISON, Wis., April 22, 2025--(BUSINESS WIRE)--Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology. B-Body Express™ allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express™ service to include standardized 2x1 and 2x2 B-Body® formats in the near future. B-Body Express™ - Validation Scale Service Features: Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales. Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation. Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility. Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon. Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms. "Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "Our B-Body Express™ service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability." The B-Body® platform is engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieve yields of 6–11 g/L, >95% purity after a single purification step, and exhibit excellent stability and viscosity profiles—ideal for subcutaneous administration and standard manufacturing workflows. Starting from validated partner sequences, B-Body Express™ manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development. About Invenra Inc. Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the new B-Body Express™ service, to accelerate the journey of novel medicines to patients. View source version on Contacts Bryan Glaser, Vice President of Business Developmentbglaser@ 608-441-8319https://
